All In Biotech

Drug Trial Radar · NCT07059845

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Nov 13, 2025

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 3 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. In substudy 3, arms F and G, participants will receive one of two doses of MIRV with BEV and carboplatin, followed by MIRV with BEV. Approximately 400 participants will be enrolled in the study at 100 sites around the world. Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused carboplatin and Bev, or IV infused Bev alone. The total study duration will be approximately 40 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions

  • Ovarian Cancer

Interventions

  • Mirvetuximab SoravtansineDrug

    Intravenous (IV) infusion

  • BevacizumabDrug

    IV Infusion

  • CarboplatinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3)Time frame: Up to Approximately 40 Months
  2. Substudy 1, 2, and 3: Number of Participants with TEAEs Leading to DiscontinuationTime frame: Up to Approximately 40 Months
  3. Substudy 1, 2, and 3: Number of Participants with Ocular Adverse Events (AEs) (any grade, Grade >= 2)Time frame: Up to Approximately 40 Months
  4. Substudy 1, 2, and 3: Overall Response (OR) as Assessed by the Investigator per RECIST v1.1Time frame: Up to Approximately 40 Months
  5. Substudy 1: Progression free survival (PFS) as Assessed by the Investigator per RECIST v1.1Time frame: Up to Approximately 40 Months

Locations

86 sites in 8 countries. Site status is shown where the registry gives one.

  • UC San Diego Health - Moores Cancer Center /ID# 277574

    La Jolla, California · Recruiting

  • Sansum Clinic - Solvang /ID# 277712

    Solvang, California · Active not recruiting

  • University of Florida College of Medicine /ID# 278348

    Gainesville, Florida · Recruiting

  • Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists - North /ID# 278626

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - East /ID# 278605

    West Palm Beach, Florida · Recruiting

  • Baptist Health Lexington /ID# 278267

    Lexington, Kentucky · Recruiting

  • Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440

    Baton Rouge, Louisiana · Recruiting

  • Maine Medical Center - Scarborough Campus /ID# 277205

    Scarborough, Maine · Recruiting

  • UMass Memorial Medical Center - Belmont Street /ID# 278628

    Worcester, Massachusetts · Recruiting

  • Karmanos Cancer Institute - Detroit /ID# 277085

    Detroit, Michigan · Recruiting

  • Intermountain Health - Intermountain Health West End Clinic /ID# 278470

    Billings, Montana · Recruiting

  • Md Anderson Cancer Center At Cooper /ID# 278390

    Camden, New Jersey · Recruiting

  • Columbia University Medical Center /ID# 277990

    New York, New York · Recruiting

  • SUNY Upstate Medical University - Syracuse /ID# 277245

    Syracuse, New York · Recruiting

  • FirstHealth of the Carolinas- Speciality Center /ID# 278636

    Pinehurst, North Carolina · Recruiting

  • Jamescare Gynecologic Oncology At Mill Run /ID# 277951

    Hilliard, Ohio · Recruiting

  • Willamette Valley Cancer Institute and Research Center /ID# 277714

    Eugene, Oregon · Recruiting

  • Penn Medicine University of Pennsylvania Health System /ID# 277963

    Philadelphia, Pennsylvania · Recruiting

  • Western Pennsylvania Gynecologic Oncology /ID# 278632

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute - Sioux Falls /ID# 278627

    Sioux Falls, South Dakota · Recruiting

  • University Of Tennessee Medical Center /ID# 278225

    Knoxville, Tennessee · Recruiting

  • Texas Oncology - Abilene - Antilley Road /ID# 277739

    Abilene, Texas · Recruiting

  • University of Texas - Southwestern Medical Center /ID# 278289

    Dallas, Texas · Recruiting

  • Texas Oncology - Fort Worth Cancer Center /ID# 277989

    Fort Worth, Texas · Recruiting

  • Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735

    San Antonio, Texas · Recruiting

  • Texas Oncology - The Woodlands /ID# 277926

    The Woodlands, Texas · Recruiting

  • Texas Oncology - Northeast Texas /ID# 277737

    Tyler, Texas · Recruiting

  • Virginia Commonwealth University Medical Center /ID# 277932

    Richmond, Virginia · Recruiting

  • Virginia Mason Hospital and Medical Center /ID# 277259

    Seattle, Washington · Recruiting

  • West Virginia University Hospitals /ID# 278965

    Morgantown, West Virginia · Recruiting

  • St. George Private Hospital /ID# 276570

    Kogarah, New South Wales, Australia · Recruiting

  • Chris O'Brien Lifehouse /ID# 276337

    Sydney, New South Wales, Australia · Recruiting

  • Icon Cancer Centre Wesley /ID# 277199

    Auchenflower, Queensland, Australia · Recruiting

  • Burnside War Memorial Hospital /ID# 277602

    Adelaide, South Australia, Australia · Recruiting

  • Icon Cancer Centre Hobart /ID# 277688

    Hobart, Tasmania, Australia · Recruiting

  • Monash Health - Monash Medical Centre - Clayton /ID# 276984

    Clayton, Victoria, Australia · Recruiting

  • Barwon Health /ID# 277297

    Geelong, Victoria, Australia · Recruiting

  • Austin Hospital /ID# 276534

    Melbourne, Victoria, Australia · Recruiting

  • Epworth HealthCare /ID# 276347

    Richmond, Victoria, Australia · Recruiting

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.